Sign In
Buy CERE
$44.96
+0 (+0%)
At Close: Oct 30, 2024
NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you inv
NEW YORK, NY / ACCESSWIRE / May 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVi
CERE SHAREHOLDERS: Cerevel Shareholders are Encouraged to Inquire About BFA Law's Investigation into the $45 Merger Offer Being Too Low
03:34pm, Thursday, 30'th May 2024
NEW YORK, NY / ACCESSWIRE / May 30, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you inv
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
12:00pm, Thursday, 30'th May 2024
NEW YORK, NY / ACCESSWIRE / May 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVi
PHILADELPHIA , May 30, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) ("Cerevel") on behalf of the company's shareholders.
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
01:04pm, Wednesday, 29'th May 2024
NEW YORK--(BUSINESS WIRE)---- $ABBV #classaction--Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:
PHILADELPHIA , May 20, 2024 /PRNewswire/ -- Shareholder protection law firm Kaskela Law LLC announces that it is investigating Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) ("Cerevel") on behalf
Amalgamated Bank Has $425,000 Stock Holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)
05:04am, Monday, 20'th May 2024
Amalgamated Bank raised its position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Free Report) by 8.8% in the 4th quarter, according to the company in its most recent filing with the Se
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared wi
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) to AbbVie Inc. for $45.00 per share in
Cramer names biopharma companies to watch as industry mergers start to pile up
07:02pm, Friday, 05'th Jan 2024
CNBC's Jim Cramer pointed out the numerous mergers and acquisitions across the biopharma industry.
Cerevel Therapeutics Holdings, Inc. (CERE)'s Technical Outlook is Bright After Key Golden Cross
11:17am, Tuesday, 19'th Dec 2023
From a technical perspective, Cerevel Therapeutics Holdings, Inc. (CERE) is looking like an interesting pick, as it just reached a key level of support. CERE's 50-day simple moving average crossed abo
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cerevel Ther
AbbVie Buys Cerevel Therapeutics for $8.7B, Bolstering Neuroscience Portfolio
05:40pm, Thursday, 07'th Dec 2023
Cerevel Therapeutics Holdings (CERE) shares jumped more than 11% Thursday after AbbVie (ABBV) agreed to acquire the neuroscience drugmaker for about $8.7 billion.
AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say
01:35pm, Thursday, 07'th Dec 2023
AbbVie's decision to buy Cerevel Therapeutics before key data on the drug developer's experimental schizophrenia treatment may have helped it avoid a potential bidding war but comes with several risks
